Moving from cancer burden to cancer genomics for smoldering myeloma: A review Review


Authors: Maura, F.; Bolli, N.; Rustad, E. H.; Hultcrantz, M.; Munshi, N.; Landgren, O.
Review Title: Moving from cancer burden to cancer genomics for smoldering myeloma: A review
Abstract: Importance: All patients who develop multiple myeloma have a preceding asymptomatic expansion of clonal plasma cells, clinically recognized as monoclonal gammopathy of undetermined significance or smoldering multiple myeloma (SMM). During the past decade, significant progress has been made in the classification and risk stratification of SMM. Observations: This review summarizes current clinical challenges and discusses available models for risk stratification in the context of SMM. Owing to several novel, more effective, and less toxic drugs, these aspects are becoming increasingly important to identify patients eligible for early treatment. However, all proposed criteria were built around indirect markers of disease burden and therefore are generally able to identify a fraction of patients with SMM in whom transformation to multiple myeloma and genomic subclonal diversification are already happening. In contrast, next-generation sequencing approaches have the potential to identify myeloma precursor disease that will progress even before the major clonal expansion and progression, providing a potential base for more effective treatment and better precision regarding the optimal timing of treatment initiation. Conclusions and Relevance: Owing to modern technologies, in the near future, prognostic models derived from genomic signatures independent of the disease burden will allow better identification of the optimal timing to treat a plasma cell clonal disorder at the very early stages, when the chances of eradication are higher. © 2019 American Medical Association. All rights reserved.
Journal Title: JAMA Oncology
Volume: 6
Issue: 3
ISSN: 2374-2437
Publisher: American Medical Association  
Date Published: 2020-03-01
Start Page: 425
End Page: 432
Language: English
DOI: 10.1001/jamaoncol.2019.4659
PUBMED: 31830214
PROVIDER: scopus
PMCID: PMC7430066
DOI/URL:
Notes: Review -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Carl Ola Landgren
    336 Landgren
  2. Even Holth Rustad
    43 Rustad
  3. Francesco Maura
    56 Maura